Evobrutinib Completed Phase 1 Trials for Hepatic Impairment Treatment

IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT04546789Effect of Hepatic Impairment on M2951 (BTK Inhibitor) PK